It is not a good idea to run a cancer clinical trial where the experimental (drug) arm is populated by treatment-naive pts and a placebo arm is populated by treatment-refractive pts.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.